This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Sep;13(9):850-1.

doi: 10.1016/S1470-2045(12)70367-4. Epub 2012 Aug 9.

A roadmap for accelerated drug approval in breast cancer?

Jose Perez-Garcia¹, Javier Cortes

Affiliations

PMID: 22884504
DOI: 10.1016/S1470-2045(12)70367-4

Comment

A roadmap for accelerated drug approval in breast cancer?

Jose Perez-Garcia et al. Lancet Oncol. 2012 Sep.

. 2012 Sep;13(9):850-1.

doi: 10.1016/S1470-2045(12)70367-4. Epub 2012 Aug 9.

Authors

Jose Perez-Garcia¹, Javier Cortes

Affiliation

¹ Breast Cancer Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

PMID: 22884504
DOI: 10.1016/S1470-2045(12)70367-4

No abstract available

PubMed Disclaimer

Comment on

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Ismael G, et al. Lancet Oncol. 2012 Sep;13(9):869-78. doi: 10.1016/S1470-2045(12)70329-7. Epub 2012 Aug 9. Lancet Oncol. 2012. PMID: 22884505 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information